Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. - Wikidata - awgldk - TriplyDB

Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption.

Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption.

http://www.wikidata.org/entity/Q40706735

about

A new insight into hepatitis C vaccine development Hepatitis C virus relies on lipoproteins for its life cycle Host restriction factors for hepatitis C virus Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection Hepatitis C virus comes for dinner: How the hepatitis C virus interferes with autophagy Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization Human immunodeficiency virus and heparan sulfate: from attachment to entry inhibition Basic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein e2 contribute to virus entry.Association between Hepatitis C Virus and Very-Low-Density Lipoprotein (VLDL)/LDL Analyzed in Iodixanol Density Gradients Viral and Cellular Determinants of the Hepatitis C Virus Envelope-Heparan Sulfate Interaction Role of the Low-Density Lipoprotein Receptor in Entry of Bovine Viral Diarrhea Virus Sulfated Homologues of Heparin Inhibit Hepatitis C Virus Entry into Mammalian Cells Binding of liver derived, low density hepatitis C virus to human hepatoma cells Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor Persistent growth of a human plasma-derived hepatitis C virus genotype 1b isolate in cell culture A novel small molecule inhibitor of hepatitis C virus entry Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell culture Promising candidates for the treatment of chronic hepatitis C.Recombinant hepatitis C virus-envelope protein 2 interactions with low-density lipoprotein/CD81 receptors.HCV infection of the transplanted liver: changing CD81 and HVR1 variants immediately after liver transplantation.Direct binding of the ligand PSG17 to CD9 requires a CD9 site essential for sperm-egg fusion.A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy.Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.Proteoglycans act as cellular hepatitis delta virus attachment receptors.Functional characterization of nuclear localization and export signals in hepatitis C virus proteins and their role in the membranous web.Differential expression of candidate virus receptors in human T lymphocytes prone or resistant to infection with patient-derived hepatitis C virus.Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry.Hepatitis C virus therapies: current treatments, targets and future perspectives.Lipid metabolism and HCV infection Characterization of hepatitis C virus interaction with heparan sulfate proteoglycans.Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantation Modeling hepatitis C virus infection using human induced pluripotent stem cells.Hepatitis C virus infection of human T lymphocytes is mediated by CD5.A Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I.Hepatitis C virus utilizes lipid droplet for production of infectious virus.MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells Hepatitis C virus entry.Identification of transferrin receptor 1 as a hepatitis C virus entry factor

P2860

Q21296858-F8E1036A-315A-455D-99C9-54A3DF5F824D Q26766119-76650AB8-186F-469A-BF31-E95596889324 Q26773258-B13495C9-C1D2-43AC-B934-BD822309D674 Q26779128-864BB5A4-CFDE-46D3-A091-52D702B4A540 Q26801207-E7431A00-4F56-4B71-AB0F-70A9EC57B7C2 Q26864485-598CDFAA-2A5F-403E-8753-511CBC02FBBA Q27004059-D9705C7F-1203-4BD5-9405-9F985D6D530E Q27472768-EBD23957-CCCD-4878-98F6-6BC9961DA118 Q27473044-2DC4174A-112D-4C8F-B622-1AF015CD3A73 Q27477606-1A949F4C-6054-4B76-8FB5-C59CC4C3E3EE Q27477607-E82625C2-7321-4151-B1C7-A90A6210BDB2 Q27478383-BE0A0AAE-4376-45F4-9916-82BBF7EC4AC3 Q27486525-E73E0DD5-0E37-486B-9ABC-9497F0362453 Q27490234-6A9F50F5-4171-484C-9484-C7C89581C1CA Q28473992-7FC6D297-0414-4151-9E8E-82DF0887822B Q28475468-36196292-CF82-4C8F-BD95-C00327D46DC0 Q28482494-879944E1-D96C-417D-9BBA-DB420CBF957C Q30333233-573D2450-5678-4712-B2B0-B8F27DCCA271 Q30375044-80E2E29B-E663-4987-8C7C-8164652686A8 Q30438047-7A34BAC3-A028-411B-8243-C34DDF6F0BD5 Q33763806-0915B85A-65B9-4BA9-BDA5-E51C992F939C Q34009510-EFF823B9-77D0-4954-AB80-390132308530 Q34016463-EC8B58C7-6982-4902-944F-386161D81C14 Q34594739-0D33F3AF-BFFC-4007-B3EB-46BF41355DCC Q34594986-DA6694EA-1244-4BEA-80A0-5FD025C9FEC7 Q34625734-04591408-863D-45BA-8291-9F96269D0FF4 Q34653969-A9956E6F-2F1A-49D3-9F1D-FAFBED7F30AA Q34692827-4E7D7F5F-56C3-40C3-844A-B2E0611FA77B Q34908895-E3D3AD02-00AD-4F6F-A2FC-1E73E9C09B53 Q35147050-5B267941-B62F-4EC2-87C1-498160498E30 Q35275932-512001EF-421C-41C2-8466-528AB6248197 Q35488198-7E001E38-2E90-452E-8BF6-E3F61B933614 Q35621603-AE368ED8-9139-4D7A-A456-5F8B6464DF03 Q35787014-CCACF237-ACB2-4B6E-8201-96E55857EF63 Q35826843-89041EB0-F85E-4D70-8375-A172DCC4261D Q36133495-99C8E381-268E-438D-97B0-32C3DD7EF73D Q36580492-7E2629F7-0EE2-460B-951D-34638D9E17E8 Q36759971-BE995F6F-3F5F-437C-8BEF-702C307B55BB Q36946317-D80CB850-D996-432C-A7C1-DE013ACDD1F3 Q36967731-0593B18E-3840-4123-A40F-1C71A04F3241

P2860

Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption.

http://www.wikidata.org/entity/Q40706735

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

2002年论文

@zh

2002年论文

@zh-cn

name

Cellular glycosaminoglycans an ...... hepatitis C virus adsorption.

@en

type

label

Cellular glycosaminoglycans an ...... hepatitis C virus adsorption.

@en

prefLabel

Cellular glycosaminoglycans an ...... hepatitis C virus adsorption.

@en

P1433

Q40706735-10FAC7FF-FE96-4C6A-867D-7DDE8E79F06A

P1476

Q40706735-519D412C-7DC5-4B88-A3B7-007D35093508

P2093

Q40706735-0F010AB0-AB13-4EB4-A0AF-83A389A76E67

Q40706735-482DE4FC-64C8-41A6-86AA-94CC11940ADB

Q40706735-83DC40F8-BC46-49A4-9EC6-0D88BD010D9B

Q40706735-93F6622E-7C37-45A2-B207-F223F528BFC4

Q40706735-94760FC9-8514-4AA8-9566-99DC40B59614

Q40706735-A54241AE-ABDA-43BA-93C8-BFDDCEC06FC2

Q40706735-D7B0304E-A1D2-452C-9979-67EF0E1BD6D6

Q40706735-E722D1A6-B11A-4811-BEAC-384BFFC0E049

P2860

Q40706735-04E94884-6EA0-4BAE-A41D-808577A99F64

Q40706735-0F4763DD-2A9C-4611-83C5-8A05801CD57A

Q40706735-126D460F-4F57-46B2-993E-780770FE7E3C

Q40706735-1770C5E4-DD1E-48BF-BE1A-D7C878192CFD

Q40706735-1786FDDC-C32B-455F-B43E-82A1A22D612E

Q40706735-190A7164-2C62-4860-AE60-AB75E9C9C314

Q40706735-2AD4BBD6-2BF5-49F7-96C8-7536662B9460

Q40706735-2B852A7F-ECE2-4679-85B0-48E526DF37AA

Q40706735-2CACBB04-C612-43BF-AB4D-1849894B8255

Q40706735-2E5DFCBC-FEE1-49F3-AEE6-85A043BF26A1

P304

Q40706735-83CBAA40-BE14-4D96-A4FD-563AB4A83CCE

P31

Q40706735-D4AAF41F-D6AC-4970-916F-200F0DF5B7D0

P356

Q40706735-A27CB5F8-C6C1-43B9-AD83-79804F77EA88

P433

Q40706735-8603F692-4E3F-4A32-9109-C5E9CEECD6C2

P478

Q40706735-F467DF5B-8FDB-4D51-A170-5410F7F64D92

P50

Q40706735-0A44BA42-5D57-4E44-9978-C466AE6E85E6

P577

Q40706735-BE37A1B4-CD5E-4661-A820-081664CE13F6

P698

Q40706735-AD5FF5E8-9441-4215-B1E2-78F179431B23

P356

P1433

Journal of Medical Virology

P1476

Cellular glycosaminoglycans an ...... hepatitis C virus adsorption.

@en

P2093

Daniel Garin

http://www.w3.org/2001/XMLSchema#string

Emmanuel Drouet

http://www.w3.org/2001/XMLSchema#string

Hugues Lortat-Jacob

http://www.w3.org/2001/XMLSchema#string

Jean-Marc Crance

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Zarski

http://www.w3.org/2001/XMLSchema#string

Josette Guimet

http://www.w3.org/2001/XMLSchema#string

Raphaële Germi

http://www.w3.org/2001/XMLSchema#string

Rob W H Ruigrok

http://www.w3.org/2001/XMLSchema#string

P2860

Binding of hepatitis C virus to CD81

Structure-function analysis of hepatitis C virus envelope-CD81 binding

Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor

Substitutions at the putative receptor-binding site of an encephalitic flavivirus alter virulence and host cell tropism and reveal a role for glycosaminoglycans in entry

Cell fusion activity of hepatitis C virus envelope proteins

Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein

Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivo

Conservation of the Conformation and Positive Charges of Hepatitis C Virus E2 Envelope Glycoprotein Hypervariable Region 1 Points to a Role in Cell Attachment

Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor

Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection

P304

206-215

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JMV.10196

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Pierre Zarski

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12210409

http://www.w3.org/2001/XMLSchema#string